Diagnostic of Human Immunodeficiency Virus (HIV) and Other Sexual Transmission Diseases (STD) in High Risk Populations: Men Who Have Sex With Men (MSM) Users of Chemsex

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03546140

Acronym

Care_ChemS

Enrollment

500

Registered

2018-06-06

Start date

2018-06-30

Completion date

2021-06-30

Last updated

2018-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

The main objective is to offer diagnostic tests for HIV, HCV and other STD in the risk group of men having sex with men (MSM) users of Chemsex

Detailed description

The main objective is to offer diagnostic tests for HIV, HCV and other STD in the risk group (MSM users of Chemsex) with the purpose of conduct diagnosis, early treatment and monitoring of this infections and reduce the incidence rate of the same ones

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (≥ 18 years) * Men MSM/transgender referred from PEP office * Men MSM/transgender referred from urgency service attended for acute intoxication or an STD * Men MSM/transgender referred from STD office * Men MSM/transgender referred from a local ONG attended for chemsex use * Specifically drug use for having sexual relations, at least once in a month in the lasts 6 months or more than 10 times the last year * Reading and understanding ability * Patients should be given written informed consent * Negative HIV and HCV men * HIV positive men but HIC negative referred from HIV daily hospital * Disposal of sanitary card from CatSalut

Exclusion criteria

* Men that not accomplish inclusion criteria * Drug use for another purposes not sexual * Drug use for having occasional sexual relations, least than once in the past 6 months

Design outcomes

Primary

Measure	Time frame	Description
Number of HIV,	2 years	HIV positive serology
number of HCV seroconversion	2 years	HCV positive serology
number STD seroconversion	2 years	positive serology

Secondary

Measure	Time frame	Description
type of consumer drug	2 years	number and name ( Visual Analog Score for drug)
weight	2 years	in kilograms
clinical outcomes	2 years	number of hospital admissions for acute intoxications
analytical outcomes	2 years	VDRL serology

Contacts

Primary ContactAnna Cruceta, MD

acruceta@clinic.ub.es932275400

Outcome results